Ultrasound contrast developer Acusphere of Tewksbury, MA, saw its net loss grow in its 2008 financial results, while the company's auditors issued a "going concern" statement regarding the company's ability to continue.
For the year (end-December 31), the company reported revenue of $2.7 million, compared with the same revenue of $2.7 million the previous year. The company posted a net loss after dividends of $69.4 million in 2008, compared with a net loss of $56 million in 2007.
For the quarter, Acusphere posted revenue of $824,000, up 23% compared to $667,000 in the same period of 2007. The company's net loss after dividends for the quarter was $33.2 million, compared with $13.1 million in the fourth quarter of 2007.
The firm said that its fourth-quarter numbers included an asset-impairment charge of $9.2 million, as well as a one-time noncash interest charge of $14.7 million.
The company's 2008 financial results will include an opinion from its accounting firm, Deloitte & Touche, regarding the company's ability to continue as a going concern. Acusphere will require "significant additional monies" to fund operations through and beyond the third quarter of 2009.
The company said that as of December 31, its balance sheet included approximately $23.1 million in total assets, comprised primarily of $16.5 million in cash and short-term investments and $4.1 million in property and equipment. As of March 31, Acusphere's unaudited cash balance was $5.7 million.
In other news, Acusphere has reacquired European marketing rights to its Imagify ultrasound contrast agent after terminating a relationship with drug firm Nycomed Danmark of Roskilde, Denmark.
Acusphere said this week that it had signed an agreement ending the deal, which was signed in 2004 and gave Nycomed rights to sell Imagify in the European Union, Russia, Turkey, and other members of the Commonwealth of Independent States. Each party agreed to incur their own expenses and that there would be no further payments to either party.
Related Reading
Acusphere plans job cuts, March 6, 2009
Acusphere amends Imagify NDA, February 19, 2009
Acusphere reports positive Imagify results, January 22, 2009
Acusphere executive resigns, January 8, 2009
FDA panel rejects Acusphere contrast agent, December 11, 2008
Copyright © 2009 AuntMinnie.com
![Overview of the study design. (A) The fully automated deep learning framework was developed to estimate body composition (BC) (defined as subcutaneous adipose tissue [SAT] in liters; visceral adipose tissue [VAT] in liters; skeletal muscle [SM] in liters; SM fat fraction [SMFF] as a percentage; and intramuscular adipose tissue [IMAT] in deciliters) from MRI. The fully automated framework comprised one model (model 1) to quantify different BC measures (SAT, VAT, SM, SMFF, and IMAT) as three-dimensional (3D) measures from whole-body MRI scans. The second model (model 2) was trained to identify standardized anatomic landmarks along the craniocaudal body axis (z coordinate field), which allowed for subdividing the whole-body measures into different subregions typically examined on clinical routine MRI scans (chest, abdomen, and pelvis). (B) BC was quantified from whole-body MRI in over 66,000 individuals from two large population-based cohort studies, the UK Biobank (UKB) (36,317 individuals) and the German National Cohort (NAKO) (30,291 individuals). Bar graphs show age distribution by sex and cohort. BMI = body mass index. (C) After the performance assessment of the fully automated framework, the change in BC measures, distributions, and profiles across age decades were investigated. Age-, sex-, and height-adjusted body composition reference curves were calculated and made publicly available in a web-based z-score calculator (https://circ-ml.github.io).](https://img.auntminnieeurope.com/mindful/smg/workspaces/default/uploads/2026/05/body-comp.XgAjTfPj1W.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
